Arming Humanity With Weapons
To Fight Drug Resistant Infections ®

About

Our mission is to decrease the quantity and severity of infections that cause human suffering and death through the creation and development of novel, targeted, antimicrobial therapies.

The Company’s lead technology, Veriox®, is a proprietary peracid/hydrogen peroxide based non-systemic, non-resistant antimicrobial agent. Veriox® features a novel Mechanism of Action that reduces the likelihood of contributing to resistance against Gram+, Gram-, viral, fungal pathogens and destroys chemical/biological warfare agents.

The Veriox® platform has numerous anti-infective surface, skin and wound care and medical device coating applications. Armis received its first FDA 510(k) clearance for its VeriFixx® Small Bone Implant in November 2020 and expects to submit an FDA application for its VeriCyn™ prescription wound wash by January 2022. See our Company Overview and Pipeline Sections for more information.

High concentration of
active agent with low
systemic exposure
Prophylactic and
therapeutic efficacy
Reduced cost of care to
hospitals, insurers,
and patients
Versatile platforms in the war
on resistant and preventable
infection
Learn More

PipeLine

Armis is focused on efficacious, non-systemic products to protect against resistant pathogens and chemical/biological warfare agents. Our products also assist in curing skin infections and improve wound healing

Learn More

Leadership Team

News

06 Oct 2021
Armis Biopharma Donates ArmisClenz™ Disinfectant to Convoy of Hope for Hurricane Ida Victims

Read More
19 Nov 2020
Armis Biopharma Announces 510(k) Clearance for VeriFixx™ Small Bone Implant

Read More
04 Nov 2020
Armis Biopharma Announces Grant Award from the National Institutes of Health

Read More

Contact Us to learn more